Controversies in the follow-up and management of well-differentiated thyroid cancer.

2004 ◽  
Vol 11 (1) ◽  
pp. 97-116 ◽  
Author(s):  
M D Ringel ◽  
P W Ladenson

Thyroid cancer is a common malignancy with an apparent increasing incidence and a wide spectrum of clinical behavior and therapeutic responsiveness. Recent advances in diagnosis, primary treatment, and long-term monitoring have led to enhanced detection of primary and recurrent disease and improvements in therapy. Controversy still surrounds several issues: the most accurate predictive staging system and histological subclassification scheme, optimal preoperative assessment and surgical extent, appropriate use of radioiodine for remnant ablation, goal for thyrotropin-suppressive thyroid hormone therapy, best practices in immediate postoperative and long-term monitoring, and approach to the patient with thyroglobulin evidence of residual disease. In this paper, recent data related to these controversial issues are critically reviewed.

2012 ◽  
Vol 97 (8) ◽  
pp. 2714-2723 ◽  
Author(s):  
A. M. Chindris ◽  
N. N. Diehl ◽  
J. E. Crook ◽  
V. Fatourechi ◽  
R. C. Smallridge

Abstract Context: Surveillance of patients with differentiated thyroid cancer (DTC) is achieved using serum thyroglobulin (Tg), neck ultrasonography (US), and recombinant human TSH (rhTSH)-stimulated Tg (Tg-stim). Objective: Our primary aim was to assess the utility of rhTSH Tg-stim in patients with suppressed Tg (Tg-supp) below 0.1 ng/ml using a sensitive assay. Our secondary aims were to assess the utility of US and to summarize the profile of subsequent Tg-supp measures. Design: This is a retrospective study conducted at two sites of an academic institution. Patients: A total of 163 patients status after thyroidectomy and radioactive iodine treatment who had Tg-supp below 0.1 ng/ml and rhTSH Tg-stim within 60 d of each other were included. Results: After rhTSH stimulation, Tg remained below 0.1 ng/ml in 94 (58%) and increased to 0.1–0.5 in 56 (34%), more than 0.5–2.0 in nine (6%), and above 2.0 ng/ml in four (2%) patients. Serial Tg-supp levels were obtained in 138 patients followed over a median of 3.6 yr. Neck US were performed on 153 patients; suspicious exams had fine-needle aspiration (FNA). All positive FNA were identified around the time of the initial rhTSH test. Six of seven recurrences were detected by US (Tg-stim >2.0 ng/ml in one, 0.8 in one and ≤0.5 in four). One stage IV patient had undetectable Tg-stim. Conclusion: In patients with DTC whose T4-suppressed serum Tg is below 0.1 ng/ml, long-term monitoring with annual Tg-supp and periodic neck US are adequate to detect recurrences. In our experience, rhTSH testing does not change management and is not needed in this group of patients.


Author(s):  
Barbara S. Minsker ◽  
Charles Davis ◽  
David Dougherty ◽  
Gus Williams

Kerntechnik ◽  
2018 ◽  
Vol 83 (6) ◽  
pp. 513-522 ◽  
Author(s):  
U. Hampel ◽  
A. Kratzsch ◽  
R. Rachamin ◽  
M. Wagner ◽  
S. Schmidt ◽  
...  

2019 ◽  
Vol 21 (1) ◽  
pp. 87 ◽  
Author(s):  
Andrea G. Locatelli ◽  
Simone Ciuti ◽  
Primož Presetnik ◽  
Roberto Toffoli ◽  
Emma Teeling

Sign in / Sign up

Export Citation Format

Share Document